

PATENT

DALE B. SCHENK *et al.*
Application No.: 09/724,288
Page 4

This listing of claims will replace all prior versions, and listings, of claims in the application:

Amendments to the Claims

Please cancel claims ~~1, 48, 60 and 68~~ without prejudice.

Claims 1-49 (Canceled)

Claim 50. (Currently Amended) A method of screening an antibody for activity in clearing a ~~biological entity physically associated with an antigen~~ tissue sample,

comprising

combining the ~~antigen-associated biological entity~~ tissue sample, the antibody and phagocytic cells bearing Fc receptors in a medium in vitro;

monitoring the amount of the ~~antigen-associated biological entity~~ tissue sample remaining in the medium, a reduction in amount of the ~~antigen-associated biological entity~~ tissue sample indicating the antibody has clearing activity against the antigen tissue sample.

Claims 51-68 (Canceled)

Claim 69. (Currently Amended) The method of claim 50, wherein the amount of the tissue sample remaining is monitored by monitoring step ~~monitors the amount of the an~~ antigen associated with the tissue sample remaining in the medium.

Claim 70. (Currently Amended) The method of claim 50, wherein the combining comprises ~~adding antigen-associated biological entity~~ combining the tissue sample to the medium, and contacting the medium with the and the antibody before adding the phagocytic cells bearing Fc receptors.

Claims 71-72 (Canceled)

Claim 73. (Previously Added) The method of claim 50, wherein the tissue sample comprises an amyloid deposit.

Q 91-100 9747-87
as originally
filed

was not tissue in 50

PATENT

DALE B. SCHENK *et al.*
Application No.: 09/724,288
Page 5

Claim 74. (Previously Added) The method of claim 73, wherein the tissue sample is from the brain of an Alzheimer's disease patient or a mammal animal having Alzheimer's pathology.

3
Claim 75. (Previously Added) The method of claim 50, wherein the antigen is A β .

Claim 76. (Previously Added) The method of claim 50, wherein the phagocytic cells are microglial cells.

Claim 77. (Currently Amended) The method of claim 50, wherein the tissue sample is selected from the group consisting of a cancerous tissue sample, a virally infected tissue sample, a tissue sample comprising inflammatory cells, a nonmalignant abnormal cell growth, and a tissue sample comprising an abnormal extracellular matrix.

Claim 78. (New) The method of claim 50, wherein the monitoring is performed microscopically.

Claim 79. (New) The method of claim 50, wherein the antibody is a monoclonal antibody.

Claim 80. (New) The method of claim 79, wherein the antibody binds to an epitope within amino acid residues 1-7 of A β .

Claim 81. (New) A method of screening an antibody for activity in clearing an isolated biological entity, comprising combining the isolated biological entity, the antibody, and phagocytic cells bearing Fc receptors in a medium in vitro, wherein the isolated biological entity is selected from the group consisting of A β , antigens of pathological microorganisms, viruses, proteoglycans, tumor antigens, and adhesion molecules;

PATENT

DALE B. SCHENK *et al.*
Application No.: 09/724,288
Page 6

monitoring the amount of the isolated biological entity remaining in the medium,
a reduction in amount of isolated biological entity indicating the antibody has clearing activity
against the isolated biological entity.

Claim 82. (New) The method of claim 81, wherein the combining comprises
combining the isolated biological entity and the antibody before adding the phagocytic cells
bearing Fc receptors.

Claim 83. (New) The method of claim 81, wherein the monitoring is
performed microscopically.

Claim 84. (New) The method of claim 81, wherein the antibody is a
monoclonal antibody.

Claim 85. (New) The screening method of claim 81, wherein the isolated
biological entity is an antigen of a pathological microorganism.

Claims 86. (New) The screening method of claim 85, wherein the antigen is a
viral antigen.

Claim 87. (New) A method of screening an antibody for activity in clearing a
biological entity physically associated with an antigen, comprising
combining the biological entity physically associated with an antigen, the
antibody, and phagocytic cells bearing Fc receptors in a medium in vitro, wherein the biological
entity is a tissue sample selected from the group consisting of a cancerous tissue sample, a tissue
sample infected with a pathogenic microorganism, a tissue sample comprising inflammatory
cells, a nonmalignant abnormal cell growth, scar tissue, and a tissue sample comprising an
abnormal extracellular matrix;

monitoring the amount of the tissue sample and the amount of antigen remaining
in the medium, a reduction in amount of the tissue sample entity and/or antigen remaining in the
medium indicating the antibody has clearing activity against the biological entity and/or the
antigen in conjunction with the phagocytic cells.

PATENT

DALE B. SCHENK *et al.*
Application No.: 09/724,288
Page 7

Claim 88. (New) The method of claim 87, wherein the monitoring is performed microscopically.

Claim 89. (New) The method of claim 87, wherein the antibody is a monoclonal antibody.

3
Claim 90. (New) A method of screening an antibody for activity in clearing an amyloid deposit, comprising combining a tissue sample comprising amyloid deposits, the antibody, and phagocytic cells bearing Fc receptors in a medium in vitro; monitoring the amount of amyloid deposits remaining in the medium, a reduction in amount of amyloid deposits indicating the antibody has clearing activity against the amyloid deposits.

Claim 91. (New) The method of claim 90, wherein the amount of amyloid deposits remaining is monitored by monitoring the amount of an antigen associated with the amyloid deposits remaining in the medium.

Claim 92. (New) The method of claim 90, wherein the combining comprises combining the tissue sample and the antibody before adding the phagocytic cells bearing Fc receptors.

Claim 93. (New) The method of claim 90, wherein the tissue sample is from the brain of an Alzheimer's disease patient or a mammal animal having Alzheimer's pathology.

Claim 94. (New) The method of claim 90, wherein the antigen is A β .

Claim 95. (New) The method of claim 90, wherein the phagocytic cells are microglial cells.

Claim 96. (New) The method of claim 90, wherein the monitoring is performed microscopically.

PATENT

DALE B. SCHENK *et al.*
Application No.: 09/724,288
Page 8

Claim 97. (New) The method of claim 90, wherein the antibody is a monoclonal antibody.

3
Claim 98. (New) The method of claim 75, wherein the antibody binds to an epitope within amino acid residues 1-7 of A β .
